{
  "image_filename": "figure_p10_det_9_000.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/figure_p10_det_9_000.png",
  "image_type": "Figure",
  "page_number": 10,
  "block_id": "det_9_000",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "A flowchart outlining pediatric influenza vaccination dosing for the 2022\u201323 season. The top box asks if the child received \u22652 doses of trivalent or quadrivalent influenza vaccine before July 1, 2022. If yes, the next step is 1 dose of 2022\u201323 vaccine; if no or unknown, the next step is 2 doses of 2022\u201323 vaccine administered \u22654 weeks apart. does not support the claim because the image provides a general dosing algorithm for children\u2019s influenza vaccination and does not mention Flublok or any pivotal trial comparing Flublok (quadrivalent) against Fluarix.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A flowchart outlining pediatric influenza vaccination dosing for the 2022\u201323 season. The top box asks if the child received \u22652 doses of trivalent or quadrivalent influenza vaccine before July 1, 2022. If yes, the next step is 1 dose of 2022\u201323 vaccine; if no or unknown, the next step is 2 doses of 2022\u201323 vaccine administered \u22654 weeks apart.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the image provides a general dosing algorithm for children\u2019s influenza vaccination and does not mention Flublok or any pivotal trial comparing Flublok (quadrivalent) against Fluarix.",
    "confidence_notes": null
  }
}